

THIS TEMPLATE IS NOT LEGAL ADVICE. TALK TO YOUR ATTORNEY FOR GUIDANCE.

တၢ်သမံသမိး COVID-19 ကသံၣ်ဒီသဒါ ဒီးတၢ်အၢၣ်လီၤတူၢ်လိာ်

တၢ်ဂ့ၢ်တၢ်ကျိၤလၢတၢ်ထၢဖျိၣ်အိၣ်လၢလံာ်က့ၢ်ဒီအပူၤအံၤ တၢ်ကစူးကါအိၣ်လၢတၢ်မၤနီၣ်မၤယါလၢနဒီးန့ၢ်ဘၣ်လံာ် ကသံၣ်ဒီသဒါ(တဖၣ်) န့ၣ်လီၤ. တၢ်ဂ့ၢ်တၢ်ကျိၤဘၣ်ယးကသံၣ်ဒီသဒါ(တဖၣ်) ဘၣ်သ့ၣ်သ့ၣ်တၢ်ကနီၤဟ့ၣ်လီၤအိၣ်ဆူၣ်ဆိၣ်ချူတၢ်မၤစၢၤအဂၤ. ကွီတဖၣ်, တၢ်အိၣ်ဆူၣ်ဆိၣ်ချူ ဝဲၤကျိၤ, ဒီးပုၤလၢအိၣ်ဒီးတၢ်မိ တၢ်ကမိၤအဂၤလၢအိၣ်လၢသဲးတၢ်ဘျုးအဖိလၢဒ်သိးကဒီးန့ၢ်ဘၣ်အိၣ်အဂၤန့ၣ်လီၤ. နမ့ၢ်အိၣ်ဒီးတၢ်သံက့ၢ်တမံၤမံၤန့ၣ်, ဝံသးစူၤသံက့ၢ်န ကသံၣ်သရၣ် မ့တမ့ၢ် ပုၤဟ့ၣ်လီၤတၢ်အိၣ်ဆူၣ်ဆိၣ်ချူတၢ်မၤစၢၤအဂၤတက့ၢ်. နမ့ၢ်အိၣ်ဒီးတၢ်သံက့ၢ်ဘၣ်ယး MIIC န့ၣ်, ကွၢ်သယံၤအံၤ www.health.state.mn.us/people/immunize/miic/public.html မ့တမ့ၢ် ကိးလိာ်တဲစိဆူ ၁-၈၀၀-၆၅၇-၃၉၇၀ တက့ၢ်.

တၢ်ဟ့ၣ်လီၤတၢ်န့ၢ်ဘျုးဒီးမုၢ်ဒါတဖၣ်လၢတၢ်ဟ့ၣ်စုအဂီၢ်- တၢ်အံၤပျဲပဆူကဒူ စရိဆူတၢ်အိၣ်ဆူၣ်ဆိၣ်ချူတၢ်တီၢ်ကျဲၤ မ့တမ့ၢ် ဒီပနံၣ် ဒီးဒ်သိးကဒီးန့ၢ် တၢ်ဟ့ၣ်စုတၢ်န့ၢ်ဘျုးဒီးမုၢ်ဒါန့ၣ်လီၤ. ဒ်လဲၣ်တဂ့ၢ်, တၢ်တဘၣ်ထုးထီၣ်ဟ့ၣ်စုနီၣ်တမံၤလၢ ကမၤန့ၢ် COVID-19 ကသံၣ်ဒီသဒါအဂီၢ်ဘၣ်, ဒီးတဘၣ်ဟ့ၣ် စုကိး ကသံၣ်ဒီသဒါအပူၤ မ့တမ့ၢ် တၢ်ဆဲးန့ၢ်ကသံၣ်အပူၤဘၣ်န့ၣ်လီၤ.

ယဟ့ၣ်ပျဲအဆူးဆူပုၤဟ့ၣ်လီၤဆူၣ်ချူတၢ်မၤစၢၤအံၤ လၢကဆူကဒူစရိဆူ ယတၢ်အိၣ်ဆူၣ်ဆိၣ်ချူတၢ်တီၢ်ကျဲၤ မ့တမ့ၢ် ပုၤအဂၤလၢအဟ့ၣ်စုလၢယခၢၣ်စး, ဒီးလၢကဒီးန့ၢ်ဘၣ်တၢ်ဟ့ၣ်စုတၢ်ဟ့ၣ်စုဒီးတၢ်န့ၢ်ဘျုးဒီးမုၢ်ဒါန့ၣ်လီၤ.

တၢ်ဆဲးကျိးတၢ်ဂ့ၢ်တၢ်ကျိၤ- ပုၤလၢအဆဲးတၢ်ကသံၣ်ဒီသဒါ

- ပုၤဆါအမံၤ (မံၤကတၢ်, ဒိၣ်ထံး, ခၢၣ်သး)-
- အိၣ်ဖျၢၣ်မုၢ်နံၤ-
- သးနံၣ်-
- လိာ်တဲစိအိၣ်ထံးတဖျၢၣ်-
- လီၤအိၣ်ဆိးထံး (ကျဲ မ့တမ့ၢ် လံာ်တးနီၣ်ဂံၢ်)-
- ဝုၢ်-
- ဟီၣ်ကဝီၤကီၢ်စဲၣ်-
- စံး(ပ)နီၣ်ဂံၢ်-
- မိၢ်အမံၤ (မံၤကတၢ်, ဒိၣ်ထံး, ခၢၣ်သး- သးနံၣ်မုၢ်စ့ၤန့ၢ် ၁၀ နံၣ်)-
- မိၢ်အမံၤကတၢ်လၢအပူၤကွီၣ် (သးနံၣ်မုၢ်စ့ၤန့ၢ် ၁၀ နံၣ်)-

တၢ်ဟ့ၣ်စုတၢ်ဂ့ၢ်တၢ်ကျိၤ

ပဲၤစိၣ်နတၢ်အုၣ်ကီၤခးကွၢ်ဒီးန့ၢ်.

- ပုၤဟ့ၣ်ဂံၢ်နီၣ်ထံးတၢ်အုၣ်ကီၤ-**
- ဖိလစံၣ်/တၢ်အုၣ်သးနီၣ်ဂံၢ် ID/ကရုဖိနီၣ်ဂံၢ်-
- ကရုၢ်အနီၣ်ဂံၢ်-

- ပုၤဟ့ၣ်တၢ်အုၣ်ကီၤမံၤဖုတဖု-**
- ဖိလစံၣ်တၢ်အုၣ်သးနီၣ်ဂံၢ် ID/ကရုဖိနီၣ်ဂံၢ်-
- ကရုၢ်အနီၣ်ဂံၢ်-

ပုၤဖိၣ်ဖိလစံၣ်, မုၢ်လီၤဆီလိာ်အသးဒီးပုၤလၢအဆဲးကသံၣ်ဒီသဒါ-

COVID-19 VACCINE SCREENING AND AGREEMENT

မံ-

အိတ်ဖျတ်မုန်-

ခိပနတ်တဟုတ်-

ခိပနတ်အမံ-

ပုလကဆဲးကသံဒီသဒါမုန်တအိတ်ဒီးတဟုတ်ကိနုတ် တိနိတ်ဖဲအံတကုတ်.

တဟုတ်လီတဟုတ်လီ

ခိဖျတ်တဟုတ်ဆဲးလီမံလကလတ်အံအယိ, ယနဟံ, ပတ်သုတ်ပတ်သး, အဟုတ်လီတဟုတ်လီ, ဒီးသးလီပလီလက-

- ယဒီးနုတ်ဘဒီးဖး မုတမုန် တဟုတ်နဟံယလက ဂုဂီဆုတ်စုးကတဟုတ်အဟုတ်လီဟုတ်ခွဲးတဟုတ်မးအသးနီဂီအကဘျဲး (Emergency Use Authorization Fact Sheet) လကသံဒီသဒါမုန်တအိတ်ထွဲထီတ်အခံအံအဂီလံ- [ဖနုတ်လီကသံဒီသဒါမုန်အမံ]တကုတ်.
- ယအိတ်တဟုတ်ဒီးတဟုတ်ယတ်လကသံကွတ်တဟုတ်သံကွတ်တဟုတ်တဟုတ်လကအိတ်ဒီးတဟုတ်စံးဆာလကအမံမံသးယလ, ဒီးယနဟံတဟုတ်နုတ်ဘျဲးတဟုတ်ဒီးတဟုတ်ယိတ်ဘုတ်ဘိလကအဘုတ်ပးဒီး COVID-19 ကသံဒီသဒါမုန်တဟုတ်ပတ်ဖျတ်ထီတ်အိတ်နုတ်လီ.
- ယအဟုတ်လီတဟုတ်လီလကဆဲး COVID-19 ကသံဒီသဒါမုန်ကစံ မုတမုန် ပုလကဆဲးလီမံအံအဂီနုတ်လီ.

ပုဆိ မုတမုန် မိဟံ/ပုကုတ်ထွဲတဟုတ် ဆဲးလီမံ- _____

မုန်- _____ / _____ / _____

တဟုတ်အိတ်ဆုတ်အိတ်ချ အတဟုတ်စံးစိ

နမုန်စံးဆာ မုန် ဆုတ်သံကွတ်တဟုတ်အံတမံမံနုတ်, ပုလကဆဲးနကသံဒီသဒါမုန်ကတကုတ် ကလိတ်ဘုတ်အိတ်ထီတ်တဟုတ်ဂုတ်တဟုတ်ကုတ်လကနအိတ်တချဲးလကဆဲးနုတ်နကသံဒီသဒါမုန်လီ-

မုန်	တမုန်	တသုတ်ညါဘုတ်	တဟုတ်သံကွတ်
မုန်	တမုန်		မုန်နမုန်ပုလကဆဲးနုတ်ဘုတ်ဘျဲးဘုတ်ဒါလကဆဲး COVID-19 ကသံဒီသဒါမုန်အဂီဂီ. <ul style="list-style-type: none"> • Pfizer-BioNTech-အသးကဘုတ်မုန် ၆ လါ မုတမုန် ပုန်နုတ်အနုတ်. • Moderna ကသံဒီသဒါမုန်-အသးကဘုတ်မုန် ၆ လါ မုတမုန် ပုန်နုတ်အနုတ်. • Novavax ကသံဒီသဒါမုန်- နသးနုတ်ကဘုတ်မုန် ၁၂ နုတ်ဒီးဆုတ်အဖိခိတ်နုတ်လီ.
မုန်	တမုန်	တသုတ်ညါဘုတ်	မုန်နအိတ်ဒီးနုတ်တဟုတ်ဂုတ်, နီခိဂံတြိဆာတလကတပွဲတဟုတ်အိတ်သးအကတဟုတ်, မုတမုန် အိ နီခိဂံတြိဆာတလကတပွဲကသံဒီကသီ မုတမုန် တဟုတ်ကုတ်ယါဘျဲးတဟုတ်ဖဲ.
မုန်	တမုန်	တသုတ်ညါဘုတ်	ကသံဒီအတဟုတ်ဒီဘုတ်လကအဒိတ်အမုန် (အဒိ, anaphylaxis) ဖဲဆဲးကသံဒီသဒါမုန်အပူကွတ်တဟုတ်မုတမုန် ဘုတ်ပးဒီး COVID-19 ကသံဒီသဒါမုန်အမံမံ.
မုန်	တမုန်	တသုတ်ညါဘုတ်	မုန်နအိတ်ဒီးတဟုတ်တဘုတ်လီဒီးသုတ်တဟုတ်ခိဆာသတဟုတ်ကလတ်, တမုန်နးနးကလတ် (၄ နုတ်ရံဂုတ်အတီပု) ဒီးတဟုတ်ဆဲး COVID-19 ကသံဒီသဒါမုန်အပူကွတ်တဟုတ် မုတမုန် သုတ်ညါ (အိတ်ဒီး) တဟုတ်တဘုတ်လီဒီးတဟုတ်ပုတ်ယုတ်လကသံဒီဆဲးဒီးသဒါမုန် မုတမုန် တဟုတ်ပုတ်ယုတ်အကတမံလတ်လတ်အပူမုန်.
မုန်	တမုန်	တသုတ်ညါဘုတ်	မုန်နအိတ်ဒီးတဟုတ်တဘုတ်လီဒီးသုတ်တဟုတ်ခိဆာသတဟုတ်ကလတ်ဒီး ကသံဒီသဒါမုန်အကတမံလတ်လတ် (တမုန် -COVID-19) မုန်တဟုတ်ကုတ်ယါဘျဲးလကအိတ်ဒီးတဟုတ်ဆဲးကသံဒီ (အဒိ ဆဲးနုတ်ကသံဒီလကညုတ်လတ်အပူ (ညုတ်ထုတ်ညုတ်ပု), လကသုတ်ကုတ်အပူ (သုတ်ကုတ်), မုတမုန် ဖဲဘုတ်ထံးဂျဲးအသိအကထာ (ဖဲဘုတ်အဖိလတ်) မုန်. တဟုတ်ပုတ်ယုတ်ဒီးတဟုတ်ဆဲးတဟုတ်တဘုတ်လီဒီးသုတ်တဟုတ်.
မုန်	တမုန်	တသုတ်ညါဘုတ်	တနုတ်အံနုတ်မိတ်လကဆဲးကုတ်.

COVID-19 VACCINE SCREENING AND AGREEMENT

မှ်	တမှ်	တသှ်ညါဘၣ်	တၢ်သံကွၢ်
မှ်	တမှ်	တသှ်ညါဘၣ်	အိၣ်ဒီးတၢ်စံၣ်စိးဘၣ်ယးဒီး တၢ်ညိးကမိထီၣ်တၢ်ဆါတဘၣ်လိာ်ဘၣ်စးအကျိအကျဲအကလုာ်ကလုာ် ဝဲဘၣ် COVID-19 တၢ်ဆါဝံအလီၢ်ခံၤ။
မှ်	တမှ်	တသှ်ညါဘၣ်	မှ်နအိၣ်ဒီးတၢ်စံၣ်စိးလၢ သးဖျါအညါထျၣ်ညိး (myocarditis) မ့တမှ် သးဖျါသလီၣ်ညိး (pericarditis) ဝဲနဆဲးဝဲဒၣ် COVID-19 ကသံၣ်ဒီးသၤအလၢအမှ် Moderna, Pfizer-BioNTech မ့တမှ် Novavax ကသံၣ်ဒီးသၤအဝံအလီၢ်ခံၤ။
မှ်	တမှ်	တသှ်ညါဘၣ်	မှ်နဆဲးတၢ်လံဝဲဒၣ်ကသံၣ်ဒီးသၤအကတမံမံဖဲအပူၤကွံာ် 4 နွံအတီၢ်ပူၤၤ။
မှ်	တမှ်	တသှ်ညါဘၣ်	တၢ်မအိၣ်လၢတၢ်ပာ်အိၣ်လီၤဖျါသးဒီးပျၤက မ့လၢဘၣ်သကၢ်ဒီးပျၤအကတလၢအိၣ်ဒီး COVID-19 တၢ်ဆါလၢတၢ်ပာ်ဂၢ်ပာ်ကျဲအီၤၤ။
မှ်	တမှ်	တဘၣ်ထွဲဘၣ်	မှ်နဆဲးဘၣ်တၢ် COVID-19 ကသံၣ်ဒီးသၤတဘျီတဘျီၤ။ မှ်နဆဲးတၢ်န့ၣ်, ကွဲးလီၤကသံၣ်ဒီးသၤအမံပနီၣ်ဒီးမှ်နလၢနဆဲးအီၤတက့ၢ်-

တဘၣ်ကွဲးတၢ်လၢလံာ်ကျိအံၤအဖီလၢဘၣ်

Vaccine information

COVID-19 Vaccine Presentation ¹	EUA Fact Sheet Date	Route ²	Manufacturer ³	Lot Number	Admin Site ⁴	Person Admin ⁵
COVID-19 (Pfizer-BioNTech bivalent) 12 years and older (gray cap), 0.3 mL		IM	PFR			
COVID-19 (Pfizer-BioNTech bivalent) 5-11 years (orange cap), 0.2 mL		IM	PFR			
COVID-19 (Pfizer-BioNTech bivalent) 6 months-4 years (maroon cap), 0.2 mL		IM	PFR			
COVID-19 (Moderna bivalent) 18 years and older (dark blue cap)		IM	MOD			
COVID-19 (Moderna bivalent) 6-11 years (dark blue cap), 0.25 mL		IM	MOD			
COVID-19 (Moderna bivalent) 6 months-5 years (dark pink cap), 0.2 mL		IM	MOD			
COVID-19 (Novavax)		IM	NVX			

1. **COVID-19 Vaccine Presentation** = lists specific product name (e.g., Pfizer-BioNTech, Moderna, Novavax, etc.)
2. **Route:** IM = Intramuscular
3. **Manufacturer:** MOD = Moderna, PFR = Pfizer, NVX= Novavax
4. **Site Vaccine Given:** LD = Left Deltoid, RD = Right Deltoid, LT = Left Thigh, RT = Right Thigh
5. **Signature or initials of person administering vaccine:** Can be used if more than one person is administering vaccines.

Signature and title of person administering vaccine: _____

Date administered: ___/___/_____

Information for health care professionals about the pre-vaccination form for COVID-19 vaccine

[For health care providers, not for the patient]

This information is derived from the [CDC: Use of COVID-19 Vaccines in the United States \(www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html\)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html). We will reference this document as CDC's Interim Clinical Considerations below and note specific sections where information can be found.

Age

Follow recommendations for vaccine administration to authorized age groups found under each vaccine product's emergency use authorization (EUA) or package insert. For Moderna, Novavax and Pfizer-BioNTech COVID-19 vaccine primary series doses, an 8-week interval is suggested between dose one and two for immunocompetent people 6 months to 64 years of age, and especially males 12-39 years.

Immediate allergic reaction

An immediate allergic reaction to a vaccine or medication is defined as any hypersensitivity-related signs or symptoms such as urticaria (hives), angioedema (painless swelling under the skin, often happens with hives), respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within four hours following administration.

Have you had a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine?

CDC considers this to be a contraindication to vaccination with COVID-19 vaccines. People with an allergy-related contraindication to one type of COVID-19 vaccine have a contraindication or precaution to the other types of COVID-19 vaccines. For additional details, refer to the following sections of CDC's Interim Clinical Considerations: Contraindications and precautions and Appendix E: Triage of people with a history of allergies or allergic reactions. For a full list of ingredients included in COVID-19 vaccines, refer to [FDA: COVID-19 Vaccines \(www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines\)](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines) and [CDC: U.S. COVID-19 Vaccine Product Information \(www.cdc.gov/vaccines/covid-19/info-by-product/index.html\)](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html).

Have you had an immediate, non-severe allergic reaction to a previous dose or known (diagnosed) allergy to a component of the COVID-19 vaccine or any of its ingredients?

CDC considers this to be a precaution to vaccination with COVID-19 vaccines. Non-severe allergic reactions may include urticaria (hives) beyond the injection site and angioedema (visible swelling) involving lips, facial skin, or skin in other locations. Angioedema affecting the airway (e.g., tongue, uvula, or larynx) would be a **severe** allergic reaction. For additional details, refer to the following sections of CDC's Interim Clinical Considerations: Contraindications and precautions and Appendix E: Triage of people with a history of allergies or allergic reactions. For a full list of ingredients included in COVID-19 vaccines, refer to COVID-19 vaccine-specific [FDA: COVID-19 Vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines) and [U.S. COVID-19 Vaccine Product Information](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html).

Immediate allergic reaction to any other vaccines (non-COVID-19) or injectable therapy (intramuscular, intravenous, or subcutaneous)? Does not include allergy shots.

People with a history of an immediate allergic reaction to a non-COVID-19 vaccine or injectable therapy that contains multiple components, one or more of which is a component of a COVID-19 vaccine, but it is unknown which component elicited the allergic reaction, have a precaution to vaccination with that COVID-19 vaccine. These people may benefit from consultation with an allergist-immunologist who can perform a more detailed risk assessment for COVID-19 vaccine receipt and possibly allergy testing. For additional details, refer to the following

COVID-19 VACCINE SCREENING AND AGREEMENT

sections of CDC's Interim Clinical Considerations: Contraindications and precautions and Appendix E: Triage of people with a history of allergies or allergic reactions.

Are you feeling sick today?

There is no evidence that someone who is sick when vaccinated will decrease the vaccine's effectiveness or increase vaccine adverse events. If a person has COVID-19 symptoms, they should isolate following current guidelines, get tested, and if necessary, seek medical care. As a precaution, when someone is moderately to severely ill, all vaccines should be delayed until the illness has improved. A person who is mildly ill (e.g., diarrhea, upper respiratory infection, etc.), can still receive a vaccine, including people who are taking an antibiotic.

People should be offered vaccination regardless of their history of symptomatic or asymptomatic COVID-19 infection, including people with prolonged post-COVID-19 symptoms. Vaccination of people with known current COVID-19 infection should be deferred until at least the person has recovered from the acute illness (if the person had symptoms) and they have met criteria to discontinue isolation. This recommendation applies to people who experience COVID-19 infection before receiving any COVID-19 vaccine dose. For details, including additional information on delaying vaccine doses, refer to the following section of CDC's Interim Clinical Considerations: COVID-19 vaccination and SARS-CoV-2 infection.

Have a history of Multisystem Inflammatory Syndrome after SARS-CoV-2 infection?

Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C and MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist (e.g., specialist in infectious diseases, rheumatology, or cardiology) is strongly encouraged to assist with decisions about the use of COVID-19 vaccines. Additional details can be found in the following section of CDC's Interim Clinical Considerations: COVID-19 vaccination and MIS-C and MIS-A section.

Have a history of myocarditis or pericarditis after a previous dose of Moderna, Pfizer-BioNTech, or Novavax COVID-19 vaccine?

CDC considers this to be a precaution to vaccination with mRNA COVID-19 vaccines (i.e., Moderna or Pfizer-BioNTech) or Novavax COVID-19 vaccine. Refer to their primary care provider to receive an assessment of their current health condition and assessment of individual benefits and risks. For more details, refer to the following section of CDC's Interim Clinical Considerations: COVID-19 vaccination and myocarditis and pericarditis.

Have you had any other vaccinations in the last 4 weeks?

Because of the observed risk for myocarditis after receipt of ACAM2000 orthopoxvirus vaccine and mRNA (i.e., Moderna and Pfizer-BioNTech) and Novavax COVID-19 vaccines and the unknown risk for myocarditis after JYNNEOS, people, particularly adolescent or young adult males, might consider waiting 4 weeks after orthopoxvirus vaccination (either JYNNEOS or ACAM2000) before receiving a Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine. However, if an orthopoxvirus vaccine is recommended for prophylaxis in the setting of an outbreak, orthopoxvirus vaccination should not be delayed because of recent receipt of a Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine; no minimum interval between COVID-19 vaccination with these vaccines and orthopoxvirus vaccination is necessary.

Have you ever received a dose of COVID-19 vaccine?

Refer to the following sections of CDC's Interim Clinical Considerations: COVID-19 vaccination overview and timing, spacing and interchangeability. Verify a person's age, what vaccine they have received, and the date(s) of prior dose(s) to assure the correct vaccine product and dose interval is used.

Other considerations

- **Chronic health condition** – is not a contraindication or precaution for vaccination.

COVID-19 VACCINE SCREENING AND AGREEMENT

- **Immunocompromised conditions** (e.g., HIV infection, immunosuppressive medications, or therapies, etc.) – immunocompromised people age 6 months and older should receive a COVID-19 vaccine series as soon as possible. They should be counseled regarding the potential for reduced immune responses and that the vaccine may not fully protect them. People need to continue to follow current guidance to protect themselves.
 - **Moderately or severely immunocompromised** – Because the immune response following COVID-19 vaccination may differ in moderately or severely immunocompromised people, CDC has specific guidance for this population. For more details refer to the following sections of the CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines: COVID-19 Vaccines, Recommendations, and Schedule for People who are moderately or severely immunocompromised.
- **Bleeding disorder or are taking a blood thinner** – recommended to use a fine-gauge needle (23 gauge or smaller) for the vaccination, followed by firm pressure on the site, without rubbing, for at least 2 minutes.
- **Dermal filler(s)** – advise to contact their health care provider for evaluation if they develop swelling at or near the site of dermal filler following vaccination. For additional details, refer to the following section of CDC’s Interim Clinical Considerations: Special Populations.
- **Pregnant** – Both CDC and ACOG urge that pregnant people be vaccinated. Pregnant and recently pregnant people with COVID-19 are at increased risk for severe illness when compared with non-pregnant people. Early data supports that vaccination is well-tolerated and elicits a protective immune response. For details, refer to the following section of CDC’s Interim Clinical Considerations: Consideration involving pregnancy, lactation, and fertility.
- **Passive antibody therapy for prevention or treatment for COVID-19** – COVID-19 vaccination can be given at any time following receipt of antibody products as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis once the isolation or quarantine period has been completed. For details, refer to the following section of CDC’s Interim Clinical Considerations: COVID-19 vaccination and SARS-CoV-2 infection.
- **COVID-19 vaccines and myocarditis and pericarditis** – Ongoing safety monitoring of the mRNA and Novavax COVID-19 vaccines has found increased risks of myocarditis and pericarditis, predominantly in males 12-39 years of age within the first week of receiving the second dose.

An 8-week interval between the first and second doses of an Moderna, Pfizer-BioNTech, and Novavax COVID-19 vaccine primary series may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis/pericarditis associated with mRNA and Novavax COVID-19 vaccines.

Clinicians should consult the following section of CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines: Safety considerations for COVID-19 vaccines or the [CDC: Clinical Considerations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis) when deciding whether to administer a COVID-19 vaccine to someone with a history of myocarditis or pericarditis or when a patient presents with symptoms of myocarditis or pericarditis.

Find EUA fact sheets for health care providers and recipients and caregivers at [FDA: COVID-19 Vaccines \(www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines\)](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines).